Clinical Trial Detail

NCT ID NCT02152956
Title Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors MacroGenics
Indications

acute myeloid leukemia

Therapies

Flotetuzumab

Age Groups: adult senior

No variant requirements are available.